Electromed Net Income Over Time
| ELMD Stock | USD 24.26 0.95 4.08% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Electromed Performance and Electromed Correlation. Electromed | Build AI portfolio with Electromed Stock |
Will Health Care Equipment & Supplies sector continue expanding? Could Electromed diversify its offerings? Factors like these will boost the valuation of Electromed. Projected growth potential of Electromed fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Electromed data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.455 | Earnings Share 1.03 | Revenue Per Share | Quarterly Revenue Growth 0.163 | Return On Assets |
Electromed's market price often diverges from its book value, the accounting figure shown on Electromed's balance sheet. Smart investors calculate Electromed's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Electromed's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Electromed's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Electromed should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Electromed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Electromed and related stocks such as Perspective Therapeutics, Helius Medical Techn, and Nano X Imaging Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CATX | (437.6 K) | (2.8 M) | (3.5 M) | (3.9 M) | (6 M) | (3.7 M) | (4.7 M) | (6.2 M) | (4.8 M) | (3.3 M) | (3.2 M) | (7.3 M) | (14.7 M) | (46.5 M) | (79.3 M) | (71.4 M) | (67.8 M) |
| HSDT | (8.5 M) | (8.5 M) | (8.5 M) | (1.1 M) | (9.8 M) | (6.9 M) | (6.9 M) | (28 M) | (28.6 M) | (9.8 M) | (14.1 M) | (18.1 M) | (14.1 M) | (8.8 M) | (11.7 M) | (10.6 M) | (11.1 M) |
| NNOX | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (22.6 M) | (43.5 M) | (61.8 M) | (105.2 M) | (60.8 M) | (53.5 M) | (48.2 M) | (50.6 M) |
| INGN | (2 M) | (2 M) | 564 K | 25.4 M | 6.8 M | 11.6 M | 20.5 M | 21 M | 51.8 M | 20.9 M | (5.8 M) | (6.3 M) | (83.8 M) | (102.4 M) | (35.9 M) | (32.3 M) | (30.7 M) |
| PROF | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (11.8 M) | (12.1 M) | (15 M) | (15.2 M) | (15.2 M) | (21.6 M) | (30.7 M) | (28.7 M) | (28.6 M) | (26.5 M) | (23.8 M) | (25 M) |
| TLSI | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (47.2 M) | (59.4 M) | (33.2 M) | (29.9 M) | (31.4 M) |
| OM | (49.8 M) | (49.8 M) | (49.8 M) | (49.8 M) | (49.8 M) | (49.8 M) | (49.8 M) | (49.8 M) | (49.8 M) | (68.3 M) | (120.7 M) | (131.9 M) | (163 M) | (172.8 M) | (128 M) | (81.7 M) | (85.7 M) |
| MXCT | (2 M) | (2 M) | (2 M) | (958.2 K) | (1.8 M) | (1.4 M) | (3.3 M) | (9.9 M) | (8.9 M) | (12.9 M) | (11.8 M) | (19.1 M) | (23.6 M) | (37.9 M) | (41.1 M) | (36.9 M) | (35.1 M) |
| INFU | (24.8 K) | (45.4 M) | (1.5 M) | 1.7 M | 3.4 M | 3.7 M | (222 K) | (20.7 M) | (1.1 M) | 1.4 M | 17.3 M | 1.4 M | 18 K | 872 K | 2.3 M | 2.7 M | 2.8 M |
| VMD | 9.5 M | 9.5 M | 9.5 M | 9.5 M | 9.5 M | 8.9 M | 1.2 M | 8.2 M | 10.2 M | 8.5 M | 31.5 M | 9.1 M | 6.2 M | 10.2 M | 11.3 M | 13 M | 11.5 M |
Electromed and related stocks such as Perspective Therapeutics, Helius Medical Techn, and Nano X Imaging Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Electromed financial statement analysis. It represents the amount of money remaining after all of Electromed operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Electromed | ELMD |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 500 Sixth Avenue |
| Exchange | NYSE MKT Exchange |
USD 24.26
Check out Electromed Performance and Electromed Correlation. For information on how to trade Electromed Stock refer to our How to Trade Electromed Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Electromed technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.